MedTrace Logo

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

NCT05215912 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2024-03-20

No results posted yet for this study

Summary

This is a Phase 1, Double blind, Single ascending and Multiple ascending dose (SAD and MAD) escalation study in Healthy Volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

TNB-738

TNB-738 is an investigation drug. Other: Matching placebo

DRUG

TNB-738

TNB-738 is an investigation drug. Other: Matching placebo

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • TeneoFour Inc.

    lead INDUSTRY

Principal Investigators

  • Ben Buelow, MD, PhD · TeneoFour Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2023-05-04
Completion
2023-07-11
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05215912 on ClinicalTrials.gov